Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prenatal exposure to pregabalin, birth outcomes and neurodevelopment - a population-based cohort study in four Nordic countries.
Dudukina E, Szépligeti SK, Karlsson P, Asomaning K, Daltveit AK, Hakkarainen K, Hoti F, Kieler H, Lunde A, Odsbu I, Rantanen M, Reutfors J, Saarelainen L, Ehrenstein V, Toft G. Dudukina E, et al. Among authors: hoti f. Drug Saf. 2023 Jul;46(7):661-675. doi: 10.1007/s40264-023-01307-2. Epub 2023 Apr 26. Drug Saf. 2023. PMID: 37099261 Free PMC article.
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Ehrenstein V, Huang K, Kahlert J, Bahmanyar S, Karlsson P, Löfling L, Nunes AP, Enger C, Bezemer ID, Kuiper JG, Hoti F, Juuti R, Korhonen P, Mo J, Schachterle SE, Wilner KD, Rørth M, Sørensen HT. Ehrenstein V, et al. Among authors: hoti f. Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):758-769. doi: 10.1002/pds.5193. Epub 2021 Jan 24. Pharmacoepidemiol Drug Saf. 2021. PMID: 33428292
Validation of safety outcomes in routinely collected data: Lessons learned from a multinational postapproval safety study.
Arena PJ, Huang K, Löfling L, Bahmanyar S, Mo J, Schachterle SE, Nunes AP, Smits E, Juuti R, Hoti F, Korhonen P, Adelborg K, Sundbøll J, Rasmussen TR, Løkke A, Ehrenstein V. Arena PJ, et al. Among authors: hoti f. Pharmacoepidemiol Drug Saf. 2023 May;32(5):592-596. doi: 10.1002/pds.5582. Epub 2022 Dec 29. Pharmacoepidemiol Drug Saf. 2023. PMID: 36495188 No abstract available.
Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study.
Strongman H, Korhonen P, Williams R, Bahmanyar S, Hoti F, Christopher S, Majak M, Kool-Houweling L, Linder M, Dolin P, Heintjes EM. Strongman H, et al. Among authors: hoti f. BMJ Open Diabetes Res Care. 2017 May 29;5(1):e000364. doi: 10.1136/bmjdrc-2016-000364. eCollection 2017. BMJ Open Diabetes Res Care. 2017. PMID: 28761650 Free PMC article.
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study.
Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW. Persson F, et al. Among authors: hoti f. Endocrinol Diabetes Metab. 2018 Aug 31;1(4):e00036. doi: 10.1002/edm2.36. eCollection 2018 Oct. Endocrinol Diabetes Metab. 2018. PMID: 30815564 Free PMC article.
59 results